Publication Information (EuropePMC) | |
Title | Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. |
PubMed ID | 28323831(Europe PMC) |
doi | 10.1371/journal.pmed.1002258 |
Publication Date | March 21, 2017 |
Journal | PLoS Med |
Author(s) | Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer JB, Karow DS, Kauppi K, Witoelar A, Karch CM, Bonham LW, Yokoyama JS, Rosen HJ, Miller BL, Dillon WP, Wilson DM, Hess CP, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Hardy J, Goate AM, Hyman BT, Schellenberg GD, McEvoy LK, Andreassen OA, Dale AM. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000026 (PHS) |
PGP000016 | Desikan RS et al. PLoS Med (2017) |
Alzheimer's disease | Alzheimer disease | 33 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000026/ScoringFiles/PGS000026.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000053 | PGS000026 (PHS) |
PSS000036| European Ancestry| 17,956 individuals |
PGP000016 | Desikan RS et al. PLoS Med (2017) |
Reported Trait: Alzheimer disease | — | — | r (correlation between between binned quantiles of PHS-predicted and empirical age of AD onset): 0.9 | APOE risk alleles (e2 and e4), age, sex, genetic PCs 1-5 | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000036 | Cases are patients with clinically diagnosed AD and compared to cognitively normal older individuals | — | [ ,
40.51 % Male samples |
— | European | — | ADGC | ADGC Phase 2 |